Capricor Therap Cmn (CAPR) 3.66 $CAPR
Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update
PR Newswire - Mon Aug 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided an update on its clinical development programs directed toward the treatment of heart disease, including that associated with Duchenne Muscular Dystrophy (DMD), as well as defined the initial development path for its proprietary exosomes technology. Capricor also announced financial results for the quarter ended June 30, 2016.
CAPR: 3.66 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 15, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held August 15, 2016 at 4:30 PM Eastern Time.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Monday, August 15 at 4:30 p.m. ET
PR Newswire - Fri Aug 12, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss second quarter 2016 financial results and recent business highlights at 4:30 p.m. ET on Monday, August 15, 2016.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.66 (+0.06)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.66 (+0.06)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.66 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.66 (+0.06)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.66 (+0.06), STAA: 8.78 (-0.16), AKER: 3.58 (-0.10), VBLT: 4.11 (+0.08)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.66 (+0.06)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), BAX: 46.73 (-0.16), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 23.82 (-0.39), CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), ABAX: 50.14 (-0.71)
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Margins Drag
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:51AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2016 adjusted earnings per share (EPS) of $2.00, up 29.9% year over year.
BSX: 23.82 (-0.39), CAPR: 3.66 (+0.06), ZBH: 129.61 (-0.26), BAX: 46.73 (-0.16)
Phibro: Animal Health Grows amid Competition from Generics
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 1:35PM CDT
On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health (PAHC).
CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), PAHC: 24.27 (+0.38), BAX: 46.73 (-0.16)
Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial
PR Newswire - Mon Apr 04, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the independent Data Safety Monitoring Board (DSMB) of the Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial has completed its pre-specified review of the first patient cohort. Based on the DSMB's recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor's lead product candidate, in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marban, Ph.D., Chief Executive Officer, is scheduled to present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 a.m. EST in New York City.
CAPR: 3.66 (+0.06)
Align Technology Tops Q4 Earnings, Revenues; Margins Drop
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 10:20AM CST
Align Technology (ALGN) ended 2015 on an impressive note, with its fourth quarter outcome squarely exceeding the Zacks Consensus Estimate
CAPR: 3.66 (+0.06), ALGN: 92.90 (-0.29), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
Thermo Fisher Tops Q4 Earnings, Affymetrix Buy in the Cards
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 12:15PM CST
Thermo Fisher (TMO) ended 2015 on a promising note, delivering a better-than-expected fourth-quarter 2015 outcome that squarely beat the Zacks Consensus Estimate
CAPR: 3.66 (+0.06), TMO: 152.19 (-0.97), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
Mead Johnson Q4 Earnings, Sales Top Estimates: Fall Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 11:55AM CST
Mead Johnson (MJN) ended 2015 on a promising note, squarely beating the Zacks Consensus Estimate in the fourth quarter of 2015.
CAPR: 3.66 (+0.06), MJN: 85.07 (+1.32), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update
PR Newswire - Mon Aug 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided an update on its clinical development programs directed toward the treatment of heart disease, including that associated with Duchenne Muscular Dystrophy (DMD), as well as defined the initial development path for its proprietary exosomes technology. Capricor also announced financial results for the quarter ended June 30, 2016.
CAPR: 3.66 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 15, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held August 15, 2016 at 4:30 PM Eastern Time.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Monday, August 15 at 4:30 p.m. ET
PR Newswire - Fri Aug 12, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss second quarter 2016 financial results and recent business highlights at 4:30 p.m. ET on Monday, August 15, 2016.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.66 (+0.06)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.66 (+0.06)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.66 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.66 (+0.06)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.66 (+0.06), STAA: 8.78 (-0.16), AKER: 3.58 (-0.10), VBLT: 4.11 (+0.08)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.66 (+0.06)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), BAX: 46.73 (-0.16), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 23.82 (-0.39), CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), ABAX: 50.14 (-0.71)
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Margins Drag
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:51AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2016 adjusted earnings per share (EPS) of $2.00, up 29.9% year over year.
BSX: 23.82 (-0.39), CAPR: 3.66 (+0.06), ZBH: 129.61 (-0.26), BAX: 46.73 (-0.16)
Phibro: Animal Health Grows amid Competition from Generics
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 1:35PM CDT
On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health (PAHC).
CAPR: 3.66 (+0.06), CSII: 24.47 (-0.10), PAHC: 24.27 (+0.38), BAX: 46.73 (-0.16)
Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial
PR Newswire - Mon Apr 04, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the independent Data Safety Monitoring Board (DSMB) of the Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial has completed its pre-specified review of the first patient cohort. Based on the DSMB's recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor's lead product candidate, in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
CAPR: 3.66 (+0.06)
Capricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marban, Ph.D., Chief Executive Officer, is scheduled to present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 a.m. EST in New York City.
CAPR: 3.66 (+0.06)
Align Technology Tops Q4 Earnings, Revenues; Margins Drop
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 10:20AM CST
Align Technology (ALGN) ended 2015 on an impressive note, with its fourth quarter outcome squarely exceeding the Zacks Consensus Estimate
CAPR: 3.66 (+0.06), ALGN: 92.90 (-0.29), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
Thermo Fisher Tops Q4 Earnings, Affymetrix Buy in the Cards
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 12:15PM CST
Thermo Fisher (TMO) ended 2015 on a promising note, delivering a better-than-expected fourth-quarter 2015 outcome that squarely beat the Zacks Consensus Estimate
CAPR: 3.66 (+0.06), TMO: 152.19 (-0.97), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
Mead Johnson Q4 Earnings, Sales Top Estimates: Fall Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jan 28, 11:55AM CST
Mead Johnson (MJN) ended 2015 on a promising note, squarely beating the Zacks Consensus Estimate in the fourth quarter of 2015.
CAPR: 3.66 (+0.06), MJN: 85.07 (+1.32), LMAT: 18.38 (-0.08), VASC: 48.17 (-0.33)
